Preparing for the EU Health Technology Assessment: Key Insights from the Upcoming 2026 Webinar

By João L. Carapinha

January 5, 2026

The European Commission is organizing a webinar set for 15 January 2026 for health technology developers of medicinal products. The event provides guidance on EU Health Technology Assessment (HTA) Regulation prep, focused on Joint Clinical Assessments (JCAs) for certain medicinal products, with topics including dossier submissions, timelines, and EU HTA Coordination Group interactions. Practical sessions will cover regulatory processes, and registration stays open until mid-January 2026.

The EU HTA Regulation (EU) 2021/2282 is key, as endorsed by the European Parliament and Council, and it sets a voluntary framework that evolves to mandatory JCAs with goals including less duplication in HTA and boosting efficiency across 27 member states. See details on official EU Health Technology webpages.

Reference url

Recent Posts

Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Therapy: A New Hope fo...

By HEOR Staff Writer

January 8, 2026

Wondering how teclistamab daratumumab therapy could change treatment options for relapsed/refractory multiple myeloma? Johnson & Johnson recently filed a Type II variation application with the European Medicines Agency (EMA), which seeks to expand TECVAYLI® (teclistamab) combined with DARZALE...
Childhood Immunization Reforms: Aligning U.S. Schedules with Global Standards

By João L. Carapinha

January 7, 2026

Aligning U.S. Childhood Immunization Schedules with International Benchmarks Recent childhood immunization reforms by the U.S. Centers for Disease Control and Prevention (CDC) follow a presidential directive...
Novartis Drug Pricing Agreement

By João L. Carapinha

Novartis reached a drug pricing agreement with the US government that lowers prices for innovative medicines, while the firm will launch future drugs at comparable prices across high-income countries. Novartis also introduces direct-to-patient platforms for Mayzent, Rydapt, and Tabrecta via Trump...